Biotech48. Chan is scatter Brained. His head is revolving in all directions. He has not, after several years, solidified the POC of the Beads. Yes, multiple revenue streams and utility of the Beads would be great...when it is time. The efficiency of versatile adoption would be exponential once there is one condition "hands down" proven efficacious for Morbidity/Mortality...not just attenuation of a cytokine surrogate storm. This is like a drug lowering the surrogates defining hyperlipidemia without backing it for Cardiovascular mortality/Morbidity. Lipitor was the highest selling drug of all time, not because it lowered cholesterol, but because it lowered cholesterol while concomitantly lowering CAD events. Chan has not established a cause and effect trial. Attenuating cytokine storm is great, but clinicians want proof of correlating events via a Large Scale well designed trial. CARS will say that is unreasonable for a small company...but that excuse does not satisfy physicians in the ER. The Market Cap has been essentially unchanged and this investment has been stagnant in light of Mutual Funds at all time record growth and value. Yes, I wish Chan would have selected one or two conditions and done it correct a LONG time ago. R2 is a start, but we are years away from POC. That being said, I do expect an uptick from the anemic linear adoption/sales trajectory that the reimbursement codes and other country(s) (ITALY for instance) may generate....but it will not be exponential as it should be by now. Things could be so much better..you have to admit. JMHO...Your...inpatient...Beloved..Pearsby
